Equities

Corcept Therapeutics Inc

Corcept Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)57.59
  • Today's Change1.67 / 2.99%
  • Shares traded473.50k
  • 1 Year change+127.27%
  • Beta0.4961
Data delayed at least 15 minutes, as of Nov 22 2024 20:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Corcept Therapeutics Incorporated have a median target of 76.00, with a high estimate of 80.00 and a low estimate of 67.00. The median estimate represents a 35.91% increase from the last price of 55.92.
High43.1%80.00
Med35.9%76.00
Low19.8%67.00

Earnings history & estimates in USD

On Oct 30, 2024, Corcept Therapeutics Incorporated reported 3rd quarter 2024 earnings of 0.41 per share. This result exceeded the 0.28 consensus of the 5 analysts covering the company and exceeded last year's 3rd quarter results by 46.43%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+11.35%
Corcept Therapeutics Incorporated reported annual 2023 earnings of 0.94 per share on Feb 15, 2024.
Average growth rate+5.22%
More ▼

Revenue history & estimates in USD

Corcept Therapeutics Incorporated had 3rd quarter 2024 revenues of 182.55m. This bettered the 171.97m consensus of the 5 analysts covering the company. This was 72.78% above the prior year's 3rd quarter results.
Average growth rate+10.25%
Corcept Therapeutics Incorporated had revenues for the full year 2023 of 482.38m. This was 20.04% above the prior year's results.
Average growth rate+12.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.